

Research and Reviews: Journal of Pharmacy and Pharmaceutical Sciences

Novel Drug Delivery Approach in Cancer Therapy

Shiva Sharma

Department of Pharmaceutics, Chandigarh College of Pharmacy, Mohali, Punjab, India.

Review Article

Received:12-06-2016

Revised: 25-06-2016

Accepted:30-06-2016

***Corresponding author:** Shiva Sharma, Chandigarh College of Pharmacy, Mohali, Punjab, India

E-mail: shivali6963@gmail.com

Keywords: Drug release, Dosage forms, Hydrogel, Cancer therapy, Novel drug delivery system, Nanoparticles, Liposomes, Microspheres, Microemulsion

ABSTRACT

Novel Drug Delivery Systems (NDDS) have numerous points of interest, which comprise better therapy by increasing the efficacy and duration of drug activity, improved patient compliance through reduced dosing frequency. It provides appropriate routes of administration and enhanced targeting for a particular site to anticipate hurtful reactions. The Different types of advanced drug delivery approach like polymeric Nano capsules, nanoparticles, liposomes, nanoemulsion, microsphere, microcapsules, hydrogels has been expressed utilizing bioactive and plant extracts. NDDS have significant advantages over conventional therapy for cancer treatment, which include improved solubility and bioavailability, low toxicity, maximum therapeutic effect, sustained and controlled drug delivery, improvement of stability and batter security from physical and biochemical degradation. This article covers the basic information and different types of Novel Drug Delivery Systems.

INTRODUCTION

Cancer is one of the major public health causes in the world. Cancer therapy still remains great challenges [1,3]. Because of the great potential application of NDDS in cancer therapy we are enabled the development of novel therapeutic and diagnostic strategies [4-6].

The particular technique by which drug is conveyed can have an impressive result on its adequacy. A few medications have an ideal focus range which maximum advantage is derived, and above or below concentration of drug from this range can be harmful or didn't produce therapeutic benefit [7,8].

Advanced drug delivery carriers should fulfill mainly two conditions. Firstly, delivery should be rate specific. Secondly, it should be site-specific. Conventional dosage forms can't meet any of these. NDDS can be divided into classes. 1) Sustained release drug delivery system. 2) Controlled release drug delivery system [9-11]. Drug delivery system is designed to produce delayed therapeutic effect over a prolonged period of time [8]. The principle objective of treatment is to accomplish consistent state blood level that is powerful and non-lethal for an extended period of time.

Advantages:

- 1) Improved patient convenience and compliance due to less frequent drug administration 2) Increase safety margin 3) Maximum utilization of drug 4) less frequency of dosing etc.
- 2) Disadvantages:
- 3) Decreased systemic availability 2) Poor in-vivo, in-vitro correlation 3) Possibility of dose dumping etc.
- 4) Controlled drug delivery follows delivery of the drug at a predetermined rate, for locally or systemically. Controlled release is splendidly zero order drug release.
- 5) Reduced dose concentration and dosing frequency 3) Reduced GI toxicity 4) Better patient acceptance.

Disadvantages:

- 1) Dose dumping
- 2) Reduce potential for precise dose measurement
- 3) Need of extra patient instruction
- 4) Stability problem.

Oral, parenteral, Transdermal and Inhalation route of administration are defined as most preferable route of administration [12-14]. NDDS strategies for local medication like nanoparticles, microspheres, polymeric micelles, liposomes, and hydrogel systems for targeting and controlled release have been examined with biodegradable and non-biodegradable polymers, comprising polyether's, polyesters, polysaccharides, poly amino-acids and proteins. These polymers are mostly utilized in cancer therapy for parenteral drug delivery system [8]. These polymers are actively known for their reduced harmful reactions and enhanced carcinostatic pharmaceutical impacts.

DIFFERENT DRUG DELIVERY SYSTEM

LIPOPROTEIN

In any ideal drug delivery system, an acceptable amount of active therapeutic drug must be assimilated and transported to the site of activity at the favorable time and rate [15].

Lipoprotein as a medication system for malignancy therapy, Lipoprotein can be utilized as a Targeted drug delivery system in malignancy therapy which helps to improve therapeutic index of anticancer agents, either by expanding the concentration of medication in tumor cells or by diminishing the interaction in normal host tissues [16,17].

Low density lipoprotein is potential transporter for chemotherapeutic mediators. They are utilized for targeted delivery of anticancer because several types of malignant cells display higher level of receptor mediated uptake of low density lipoprotein [8]. For clinical malignancy therapy liposomes and phospholipid vesicles, have been known as a potential drug delivery system [18-20]. This system protecting healthy cells from toxic effect and keep their concentration in susceptible tissues for example in patient kidneys and their liver [21-25].

NANOPARTICLE

Nanoparticles are in the solid state and are either amorphous or crystalline in nature with size range (from 10 to 200 nm) [26,27]. It secures drug against chemical and enzymatic dilapidation [28-30]. Biodegradable polymeric nanoparticles have few applications in the controlled release of therapeutic medications in targeting specific tissue or organs as carriers in gene therapy [31].

Nanomaterial classified as Nanotubes, Nanowires, Nano shells, Quantum dots, Nano pores, Gold nanoparticles [32-35].

NANOEMULSION

Nano emulsions can be characterized as oil-in-water (o/w) emulsions with mean droplet size from 50 to 200 nm and the particles can exist as both water-in-oil and oil-in water forms, where the core of the particle is whichever water or oil [8,36-40]. Nano-emulsions like microemulsion may have high optical transparency and kinetic constancy [41-44].

MICROCAPSULES

Numerous anticancer agents (such as paclitaxel, PCT; camptothecin, CPT; and certain porphyrins like meso tetraphenylporphine, TPP, utilized as a part of photodynamic treatment, PDT) with stumpy aqueous solubility affect their application and makes direct parenteral administration more complicated [45-47]. Novel drug delivery strategies based on the drug carrier systems approaches have been advised to overwhelmed their reduced solubility, little stability, and dangerous symptoms [8,48]. PEG diacyllipids conjugates have attracted much consideration towards their easily controlled properties and great pharmacological features [49-52].

MICROEMULSION

Microemulsion are defined as liquid scatterings of water and oil that are prepared thermodynamically stable formulation which is homogenous, transparent or translucent in nature by the addition of relatively huge concentration of a surfactant and a surfactant [10,53]. Microemulsion droplets diameter having range of 10-100 nm and have been extensively considered for targeted drug delivery system to the brain [54,55-57]. It is a cost effective strategy and enhances the bioavailability of the poorly dissolvable medications [58-60].

MICROSPHERES

Microsphere technology is the newest development in cancer chemotherapy. Microsphere is solid porous particles with diameters 1 - 100 μm [8,64]. It can focus on their medication load by physical trapping in blood veins known as chemoembolization and sustain therapeutic agent action through controlled release. Biodegradable microspheres are used for direct delivery of drugs to organ(s) by lodging therapeutic drug in the end organ vessels [62-65]. Its effect depends on the size and mode of administration of the microsphere either intravenous or intra-arterial [66-68].

DENDRIMERS

Dendrimers are highly branched-three-dimensional, monodisperse molecules with highly controlled structures [8]. Its monodispersed, encapsulation ability, water solubility and huge number of peripheral functional groups, make them perfect candidates for assessment as medication delivery system [69-71]. Recently, Dendrimers used as drug delivery system for anticancer drugs in variety of cancer therapies [72-78].

Mainly there are three methods used for drug delivery through Dendrimers (a) attachment of drug to periphery of the Dendrimers through covalent bond to form Dendrimers pro-drugs, (b) the drug is synchronized to the outer functional groups through ionic interactions, or (c) host-guest supramolecular assembly [79-83].

HYDROGELS

Hydrogels are three-dimensional networks of water-swollen polymers [7-9,39,55]. It usually comprises crosslinked hydrophilic polymers which cross-linked either through covalent bonds or composed by physical intramolecular and intermolecular attractions that swell readily without dissolving in aqueous solution [84-88]. Because of hydrogel unique ability to swell under biological conditions makes them an ideal class of materials for biomedical applications, for example drug delivery and tissue engineering [89-96]. Hydrogels are highly hydrophilic in nature due to the presence of some hydrophilic moieties such as carboxyl, amide, amino, and hydroxyl groups [97-100].

CONCLUSION

Novel drug delivery systems will present an opportunity for formulation researchers to overcome many challenges associated with the conventional systems. Cancer chemotherapy has been renowned as exceptional areas of need for advanced drug therapy. Lipoproteins, nanoparticles, Microspheres etc. as advanced drug delivery systems have become an attractive field of new research and measured excellent candidates with great potential in the area of novel drug delivery systems.

REFERENCES

1. Rangasamy M and Parthiban KG. Recent Advances in Novel Drug Delivery System. IJRAP. 2010;1: 316.
2. Reddy PD and Swarnalatha D. Recent advances in Novel Drug Delivery Systems. IJPTR. 2010;2: 2025.
3. Muller CC. Physicochemical characterization of colloidal drug delivery systems such as reverse micelles, vesicles, liquid crystals and nanoparticles for topical administration. European Journal of Pharmaceutics and Biopharmaceutics. 2004;58:343.
4. Ajazuddin S and Saraf. Applications of novel drug delivery system for herbal formulation. Fitoterapia. 2010;81:680.
5. Heller J and Hoffman AS. Drug delivery system, in: Ratner BD, Hoffman AS, Schoen FJ, Biomaterials Science, Elsevier Academic Press, California, USA, 2004, pp. 629.
6. Bannon-Peppas L and Blanchette JO. Nanoparticle and targeted system for cancer therapy, Adv Drug Deliv Rev. 2004;56:1649.
7. Hoffman AS. Hydrogels for biomedical applications. Adv Drug Delivery Rev 2002;54:3.
8. Swatantra KS, et al. Novel Drug Delivery System for Anticancer Drug: A Review. International Journal of PharmTech Research. 2012;4:542.
9. Gopi S, et al. Effective Drug Delivery System of Biopolymers Based On Nanomaterials and Hydrogels - A Review. Drug Des. 2016;5:2.
10. Nirmala MJ and Nagarajan R Microemulsions as Potent Drug Delivery Systems. J Nanomed Nanotechnol. 2016;7:1.
11. Mandal B. Personalized Nanotheranotics for Cancer. J Biotechnol Biomater. 2016;6:1.
12. Mohsen R, et al. Design, Synthesis, Characterization and Toxicity Studies of Poly (N-Iso- Propylacrylamide-co-Lucifer Yellow) Particles for Drug Delivery Applications. J Nanomed Nanotechnol. 2016;7:363.
13. Khaled EA, et al. Mesoporous Silica Materials in Drug Delivery System: pH/Glutathione- Responsive Release of Poorly Water-Soluble Pro-drug Quercetin from Two and Three-dimensional Pore-Structure Nanoparticles. J Nanomed Nanotechnol 2016;7:360.
14. Van Tilburg CWJ. Spinal Analgesic Drug Delivery for Ehlers-Danlos Hypermobility Type Chronic Pain Treatment: A Case Report. J Pain Relief 2016;5:235.
15. Sharma A. International Journal of Pharmaceutics. 1997;154:123.
16. Mauer N, et al. Developments in liposomal drug delivery systems. Expert Opin Biol Ther. 2001;6:923.
17. Maeda H, et al. Tumour vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000;65:271.
18. Zaman H. Addressing Solubility through Nano Based Drug Delivery Systems. J Nanomed Nanotechnol 2016;7:376.
19. Zhang L, et al. The Research on Effect-enhancing and Toxicity-reducing of Rhubarb Total Anthraquinones Caused by Oral Colon-specific Drug Delivery System When Producing Purgative Efficacy. Journal of Pharmacy and Pharmaceutical Sciences. 2016
20. Dudhipala N, et al. Amoxicillin Trihydrate Floating-Bioadhesive Drug Delivery System for Eradication of Helicobacter pylori: Preparation, In Vitro and Ex Vivo Evaluation. J Bioequiv Availab. 2016;8:118.
21. Shanmugan P and Bandameedi R. Chronotherapeutic Drug Delivery Systems. J Drug Metab Toxicol. 2015;6:1.
22. Patil JS. Hydrogel System: An Approach for Drug Delivery Modulation. Adv Pharmacoepidemiol Drug Saf 2015; 4:1.
23. Naydenov T, et al. Opinion of Bulgarian Pharmacists on Drug Delivery Systems, Orodispersible and Pediatric Dosage Forms. J App Pharm 2016;8:1.
24. Maroof K, et al. Scope of Nanotechnology in Drug Delivery. J Bioequiv Availab. 2016;8:1.
25. Wang X and Lu W. Active Targeting Liposomes: Promising Approach for Tumor-Targeted Therapy. J Bioequiv Availab. 2016;8:13.
26. Muntha P. Nanoparticles as Targeted Drug Delivery Systems? A Novel Approach in Cancer Therapy. Journal of Pharmacy and Pharmaceutical Sciences. 2013.
27. Yao Y and Costa M. Genetic and Epigenetic Effects of Nanoparticles. J Mol Genet Med. 2013;7:86.
28. Barakat NS. Target Nanoparticles: An Appealing Drug Delivery Platform. J NanomedNanotechnol. 2012;S4:009.
29. Kondrashina OV. Targeted Drug Delivery System of Gd³⁺ for Neutron Capture Therapy against Cancer is Metal organic Magnetic Nanoparticles. J NanomedineBiotherapeuticDiscov. 2013;3:116.
30. deAguiar Ferreira Cv and de Barros ALB. Aptamer Functionalized Nanoparticles for Cancer Targeting. J Mol Pharm Org Process Res. 2013;1:105.
31. Aminabhavi T.M. JCR. 2001;70;1.
32. Kumar P, et al. Synthesis of Dox Drug Conjugation and Citric Acid Stabilized Superparamagnetic Iron-Oxide Nanoparticles for Drug Delivery. Biochem Physiol 2016;5:194.

33. Jagadevappa Patil (2016) Advances in Drug Delivery Strategies for Cancer Therapeutics. *J Pharmacovigil.* 2016;S3:e002.
34. Lopes CM and Soares C. Transdermal Drug Delivery Systems Activated by Physical stimuli: Techniques and Applications. *Drug Des.* 2015;4:3.
35. Leucuta SE. A New Frontier for Nanoparticulate Drug Delivery Systems to Improve Drug Targeting and Molecular Pharmacotherapy: Subcellular Bioavailability. *Clin Pharmacol Biopharm.* 2015;4:e118.
36. Singh R, et al. NANOEMULSION: An Effective Therapy for Transdermal Drug Delivery. 2015.
37. Divya A Novel technologies of transdermal drug delivery systems. *Pharmaceutics and Nanotechnology.* 2015
38. Kotturi N (2015) Novel Drug Delivery System. *Pharmaceutics and Nanotechnology.* 2015.
39. Nasri M and Mirshekarpour H. Polymeric Nanostructures as Colloidal Drug Delivery Systems: Thermosensitive Hydrogels Containing Self-Assembled Micelles. *J Nanomed Nanotechnol.* 2015;6:301.
40. Megaji S and Thota A. Advanced Techniques in Novel Drug Delivery Systems- A short Commentary. *Pharmaceutics and Nanotechnology.* 2015.
41. Babu GK. Advancements in Novel Drug Delivery Systems and Opportunities for Indian Pharmaceutical companies. *Pharmaceutics and Nanotechnology.* 2015.
42. Gautami J. Targeted Drug delivery systems. *Pharmaceutics and Nanotechnology.* 2015.
43. Rahul J. Importance of Nanoparticles in Targeted Drug Delivery System for Treatment of Cancer: A Brief Review. *Pharmaceutics and Nanotechnology.* 2015;
44. Muntha P (2014) Nanoparticles as Targeted Drug Delivery Systems ? A Novel Approach in Cancer Therapy. *Pharmaceutics and Nanotechnology.* 2014
45. Garcia-Carbonero R, and Supko JG. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins, *Clinical Cancer Research.* 2002;8:641.
46. Singla AK, et al. "Paclitaxel and its formulation", *International Journal of Pharmaceutics.* 2002; 235:179.
47. Torchilin VP. "Structure and design of polymeric surfactant-based drug delivery systems", *Journal of Controlled Release.* 2001;73:137.
48. Colone M, et al. Redox-active Microcapsules as Drug Delivery System in Breast Cancer Cells and Spheroids. *J Mol Genet Med.* 2016;10: 200.
49. Kamel R. Transdermal Drug Delivery: Benefits and Challenges. *J App Pharm.* 2016;8:1.
50. Awan BN, et al. Bacterial and Liposomal Vector Guided Drug Delivery System via Tumor Markers Carrier Gene to Treat Neoplasm. *J App Pharm.* 2016; 8:1.
51. Bhasin S and Patel R. Enhanced Oral Bioavailability of Alitretinoin by Lipid Drug Delivery System. *Pharm Anal Acta.* 2015; 6:433.
52. Patil JS. Novel Drug Delivery Strategies: New Concepts. *Adv Pharmacoepidemiol Drug Saf.* 2015;4:e134.
53. Jain J, et al. "Formulation Development of Parenteral Phospholipid-based Microemulsion of Etoposide", *AAPS PharmSciTech.* 2010;11:826.
54. Gundogdu E, et al. A Microemulsion for the Oral Drug Delivery of Pitavastatin. *Pharmaceut Anal Acta.* 2013;4:209.
55. Aminabhavi TM Polysaccharide-Based Hydrogels as Biomaterials in Drug Delivery. *J Pharma Care Health Sys.* 2015;2: e132.
56. Guptha A. Nano drug delivery system - a mini review. *Pharmaceutics and Nanotechnology.* 2015
57. Farooq U, et al. Design and Development of Multi Particulate System for Targeted Drug Delivery Using Natural Polymer. *Pharm Anal Acta.* 2015;6:366.
58. Chintaju N, et al. Improvements in the Drug Delivery System. *Journal of Pharmacy and Pharmaceutical Sciences.* 2015
59. Kumar V, et al. Nanostructures for Drug Delivery. *J Drug Metab Toxicol.* 2015
60. Hu D, et al. The Bright Future of Liposome Mediated Drug Delivery. *Biochem Physiol.* 2015;4: e133.
61. Uckun FM. Lipid Spheres as Attractive Nanoscale Drug Delivery Platforms for Cancer Therapy. *J Nanomed Nanotechnol* 2012;3:128.
62. Pawar HA and Bhangale BD. Phytosome as a Novel Biomedicine: A Microencapsulated Drug Delivery System. *J Bioanal Biomed.* 2015;7:006.
63. Jafari S and Adibkia K. Application of Hydroxyapatite Nanoparticle in the Drug Delivery Systems. *J Mol Pharm Org Process Res.* 2015,3:1.
64. Nemade MS, et al. Novel Approaches to Colon Targeted Drug Delivery System: A Review. *PHARMACY AND PHARMACEUTICAL SCIENCES.* 2014
65. Annigeri RG and Jadhav M. Mucoadhesive Patch: A Novel Drug Delivery. *PHARMACY AND PHARMACEUTICAL SCIENCES.* 2014
66. Wen H and Li Y. Redox Sensitive Nanoparticles with Disulfide Bond Linked Sheddable Shell for Intracellular Drug Delivery. *Med Chem (Los Angeles)* 2014; 4:748.
67. Malika V, et al. Nano-Carrier for Accentuated Transdermal Drug Delivery. *J Develop Drugs.* 2014; 3:121.

68. Xiang Q and Morais PC. Remote Hyperthermia, Drug Delivery and Thermometry: The Multifunctional Platform Provided by Nanoparticles. *J Nanomed Nanotechnol* 2014;5:209.
69. Kopecek J. Soluble biomedical polymers. *Polym Med* 1977;7:191.
70. Patil J. Encapsulation Technology: Opportunity to develop Novel Drug Delivery Systems. *J Pharmacovigil* 2016;4:3.
71. Koushik OS, et al. Nano Drug Delivery Systems to Overcome Cancer Drug Resistance - A Review. *J Nanomed Nanotechnol* 2016;7:378.
72. Chen Y and Yang K. Intra-Articular Drug Delivery Systems for Arthritis Treatment. *Rheumatology (Sunnyvale)* 2012;2:e106.
73. Barakat NS, et al. (2012) Target Nanoparticles: An Appealing Drug Delivery Platform. *J Nanomed Nanotechnol* 2012;S4-009.
74. Romero EL. The Involvement of Nano-Drug Delivery in Biosafety Issues. *Biosafety* 2012;1:e108.
75. Anwunobi P and Emeje MO. Recent Applications of Natural Polymers in Nanodrug Delivery. *J Nanomed Nanotechnol* 2012;S4-002.
76. Saboktakin MR, et al. (2012) Synthesis and Characterization of Biodegradable Thiolated Chitosan Nanoparticles as Targeted Drug Delivery System. *J Nanomed Nanotechnol* 2011;S4-001.
77. Douroumis D. Mesoporous silica Nanoparticles as Drug Delivery System. *J Nanomed Nanotechnol* 2011;2:1.
78. Khan DR. The Use of Nanocarriers for Drug Delivery in Cancer Therapy. *JCST*. 2010;2:058.
79. Bheemidi VS, et al. An Imperative Note on Novel Drug Delivery Systems. *J Nanomed Nanotechnol* 2011;2:125.
80. Swain S. Mucoadhesive Micro and Nanoparticles for Oral Controlled Drug Delivery System for Prolongation of Gastric Residence and Its Application. *Pharmaceut Reg Affairs*. 2012;1:1.
81. Chauhan A. Pulmonary Drug Delivery Systems, A Versatile Technique. *Pharm Anal Acta*. 2012; 3:1.
82. Swaminathan S and Jablonski MM. Non-Biological Membranes as Drug Delivery Systems. *J Membra Sci Technol*. 2012;2:1.
83. Rui Liu. Nanostructured Lipid Carriers as the Most Promising Approach in Ocular Drug Delivery System. *J Nanomedicine Biotherapeutic Discov*. 2012;2:1.
84. Saktioto T, et al. Drug Delivery System Model using Optical Tweezer Spin Control. *J Biosens Bioelectron* 2014;5:159.
85. Punthawanunt S and Yupapin PP. Drug Delivery Targeting Security by Optical Capsule Switching Control. *J Biosens Bioelectron*. 2014;5:158.
86. Singh M, et al. Drug Delivery System for Controlled Cancer Therapy Using Physico-Chemically Stabilized Bioconjugated Gold Nanoparticles Synthesized from Marine Macroalgae, *Padina Gymnospora*. *J Nanomed Nanotechnol*. 2014;S5-009.
87. Dutta AK and Ikiki E. Novel Drug Delivery Systems to Improve Bioavailability of Curcumin. *J Bioequiv Availab*. 2014;6:001.
88. Babar MM, et al. Virosomes-Hybrid Drug Delivery Systems. *J Antivir Antiretrovir*. 2013;5:166.
89. Peddi MG. Novel Drug Delivery System: Liquid Solid Compacts. *J Mol Pharm Org Process Res* 2013;1:108.
90. Al-Achi A and Lawrence JBS. Micelles: Chemotherapeutic Drug Delivery. *Clin Pharmacol Biopharm* 2013;2:1.
91. Gou M. Promising Application of Nanotechnology in Anticancer Drug Delivery. *Drug Des* 2013;2:1.
92. Kumar RS, et al. Self Nanoemulsifying Drug Delivery System of Olanzapine for Enhanced Oral Bioavailability: In vitro, In vivo Characterisation and In vitro -In vivo Correlation. *J Bioequiv Availab*. 2013;5:201.
93. Gallud A, et al. Functionalized Nanoparticles for Drug Delivery, One- and Two-photon Photodynamic Therapy as a Promising Treatment of Retinoblastoma. *J Clin Exp Ophthalmol*. 2013;4:288.
94. Zhu Y. Mesoporous Silica Nanoparticles with a Core-Shell Structure for Drug Delivery. *J Bioanal Biomed*. 2013;5:1.
95. Weston GS and Yeboah KG. Site-Specific Drug Delivery to the Gastrointestinal Tract. *J Mol Pharm Org Process Res*. 2013;1:1.
96. Al-Ghananaeem A. Sublingual and Nasal Transmucosal Drug Delivery for Breakthrough Pain: A Frontier in Cancer Therapy. *J Bioequiv Availab*. 2013;5:1.
97. Hassan BAR. Overview on Drug Delivery System. *Pharm Anal Acta*. 2012;3:1.
98. Nayak UY. Role Of Nano-Particles In Drug Therapy-Drug Delivery Approach. *Drug Des* 2012;S5:1.
99. Hoare TR and Kohane DS. Hydrogels in drug delivery: Progress and challenges. *Journal of Pharmaceutics*. 2008;49:1993.
100. Ahmadi F, et al. Chitosan based hydrogels: characteristics and pharmaceutical applications. *Res Pharm Sci*. 2015;10:1.